Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | rearrange |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | KIT rearrangement indicates an unspecified rearrangement of the KIT gene. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT rearrange |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02029001 | Phase II | Durvalumab + Tremelimumab Olaparib Pazopanib Nilotinib | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (MOST plus) | Recruiting | FRA | 0 |
NCT01831726 | Phase II | Dovitinib | Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib | Completed | USA | 0 |
NCT02400385 | Phase II | Nivolumab + Sunitinib | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | Withdrawn | USA | 0 |